Health Canada Ponders UK Model On Easing Biosimilar Study Requirements
US FDA Stand Unchanged For Now
Executive Summary
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.